EXTRUDED PHARMACEUTICALS LTD

Extruded Pharmaceuticals Ltd has developed ChemoSeed®, an implantable device designed to be implanted at the surgical margin of hard-to-treat cancers such as brain and pancreatic cancer as well as other solid tumours such as prostate, breast, bladder, lung and liver cancer. ChemoSeed improves the clinical performance of new and currently available oncology drugs by delivering them directly to the tumour tissue/cancer cells improving efficacy while reducing toxicity/side effects. Our first ChemoSeed is being developed for the localised treatment of brain tumours. This ChemoSeed has completed all preclinical testing and we currently have a sterilised GLP batch available for biocompatibility testing before entering a Phase II registration quality clinical trial in Q4 of 2024. Extruded Pharmaceuticals Ltd have the capability to formulate any API into ChemoSeed and take it from formulation development, through technology transfer, scale-up and GLP toxicity testing onto clinical batch supply for clinical trials.